TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07204314: A Randomized, Double-blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Once-Daily Oral Administration of Vortioxetine in Japanese Pediatric Patients 12 to 17 Years of Age Wi

Sponsor: Takeda · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 180 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,738,856

Rescue Site Savings

+$7,731,616

Unlock Full NCT07204314 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07204314 Rescue Dossier →